Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harmony Biosciences Holdings, Inc. filings document a commercial-stage pharmaceutical issuer focused on rare neurological diseases and its WAKIX-centered operating results. Form 8-K reports furnish quarterly and annual financial results, preliminary net product revenue, revenue guidance, investor presentations, and clinical-program updates.
Governance filings include definitive proxy materials for annual meeting matters, board elections, executive compensation, and shareholder voting procedures. Material-event reports also record executive appointments, separations, compensatory arrangements, board changes, Regulation FD disclosures, and exhibit-based updates related to the company’s business and pipeline.
Harmony Biosciences Holdings, Inc. (HRMY) reported that Chief Medical Officer Kumar Budur exercised stock options for a total of 22,954 shares of common stock on September 8, 2026, at exercise prices of $30.69 and $30.27 per share. On September 4 and 8, 2026, he sold an aggregate of 33,954 shares of common stock in open-market transactions at weighted average prices between approximately $41.51 and $43.20 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan.
Harmony Biosciences Holdings, Inc. (HRMY) received a Rule 144 notice from officer Kumar Budur covering the proposed sale of up to 28,454 shares of common stock through Morgan Stanley Smith Barney LLC. The shares have an aggregate market value of $1,202,181.50 and are listed on NASDAQ, with 58,236,393 shares outstanding as of September 8, 2026.
The shares to be sold were acquired from vested restricted stock units between January 24, 2025 and January 25, 2026, from the employee stock purchase plan on November 30, 2022 and May 31, 2023, and from the exercise of stock options on September 8, 2026. In the prior three months, Budur reported a 10b5-1 sale of 5,500 shares for proceeds of $230,911.45.
Harmony Biosciences Holdings, Inc. (HRMY) received a Rule 144 notice from executive Kumar Budur covering the proposed sale of 5,500 shares of common stock through Morgan Stanley Smith Barney. The shares were acquired from vesting restricted stock units between January 24, 2025 and January 25, 2026.
Harmony Biosciences shareholder VALOR IV PHARMA HOLDINGS LLC filed to sell up to 700,883 shares of common stock, which were acquired on 10/06/2017 through a Private Acquisition from Issuer/Affiliate for cash. The class of common stock has an aggregate market value of $26,563,465.70 and 58,236,393 shares outstanding as of 08/07/2026 on NASDAQ; this is a baseline figure, not the amount being sold. The filing also lists prior sales over the past three months totaling 116,490 shares for approximately $4,332,549.00.
Harmony Biosciences Holdings, Inc. reported higher profitability for Q2 2026, with net product revenue of 261,280 (in thousands) versus 200,489 a year earlier and net income of 75,431 versus 39,776. Diluted earnings per share were 1.28 compared with 0.68.
For the first six months of 2026, net product revenue reached 476,667 and net income was 107,919. Operating cash flow was 120,192, and cash, cash equivalents and investments totaled 962,459 as of June 30, 2026; the company states this should meet operational needs for at least twelve months. Long-term debt principal outstanding was 155,000.
WAKIX remains the only commercial product, while the pipeline includes a Phase 3 Prader–Willi syndrome study and new pitolisant formulations. An NDA for Pitolisant GR has been accepted with a PDUFA date of April 1, 2027. The company has settled several generic WAKIX ANDA actions with licensed entry generally around 2030, while other patent and antitrust-related proceedings continue.
Harmony Biosciences Holdings, Inc. reported record Q2 2026 results, with net product revenue of $261.3 million for WAKIX, representing 30% year-over-year growth and supporting reiterated 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
Average treated patients were about 8,950, an increase of 450. Cost of product sold was $63.2 million, or 24.2% of net product revenue, primarily reflecting new royalties related to the Novitium license agreement. Net income was $75.4 million, or $1.28 per diluted share, compared with $39.8 million, or $0.68, in Q2 2025. As of June 30, 2026, cash, cash equivalents and investments totaled $962.5 million, and stockholders’ equity was $999.2 million versus $870.2 million at year-end 2025.
The company also highlighted pipeline and regulatory progress. Phase 1 single ascending dose data for orexin-2 agonist BP-205 showed favorable pharmacokinetic and safety/tolerability profiles, with additional Phase 1 and Phase 2 studies planned through 2027. The NDA for Pitolisant GR was accepted with a target PDUFA date of April 1, 2027, while Pitolisant HD is expected to deliver Phase 3 topline data in 2027 and has a target PDUFA date in 2028.
Vanguard Portfolio Management filed a beneficial ownership report on Harmony Biosciences Holdings Inc common stock. Vanguard reports beneficial ownership of 2,943,383 shares, representing 5.08% of the outstanding common stock. Vanguard has sole voting power over 62,894 shares and sole dispositive power over 2,943,383 shares, with no shared voting or dispositive power. The position includes securities held by specified Vanguard affiliates and funds over which they exercise voting and/or dispositive power, and no other individual person’s interest exceeds 5% of the class.
BlackRock, Inc. reports beneficial ownership of 6,525,663 shares of Harmony Biosciences Holdings, Inc. common stock, representing 11.3% of the class. BlackRock has sole voting power over 6,445,523 shares and sole dispositive power over 6,525,663 shares, with no shared voting or dispositive power.
The shares are held across certain BlackRock business units, and various underlying persons have rights to dividends or sale proceeds, but no single such person holds more than five percent of Harmony Biosciences’ outstanding common shares.
Harmony Biosciences Holdings, Inc. reports that officer Stephen M. Mollichella, whose title is listed as "INT PRINCIAL FINANCIAL OFFICER", beneficially holds stock options over 12,172, 8,500, 7,050 and 20,750 shares of common stock with exercise prices from 30.6900 to 38.0100, expiring between 2031 and 2036. He also holds restricted stock units over 2,625, 3,488 and 5,900 shares that vest in annual installments beginning in 2027, subject to continued service, and 2,506 shares of common stock directly.
Harmony Biosciences reported preliminary, unaudited Q2 2026 net product revenue for WAKIX of approximately $261 million, a record quarterly level, with 30% year-over-year and 21% sequential growth. The company reaffirmed full‑year 2026 net product revenue guidance of $1.0 billion to $1.04 billion, reflecting confidence based on first‑half performance.
Harmony also announced leadership changes. Chief Financial Officer Glenn Reicin stepped down effective July 16, 2026, under a Separation Agreement providing severance and a prorated target bonus consistent with his employment terms; the company stated his departure was not due to any disagreement on operations, policies or practices. Senior Vice President and Controller Stephen Mollichella was appointed Interim Principal Financial Officer, providing continuity in finance leadership. Harmony will report full Q2 2026 financial results and provide a business update on August 4, 2026.